Serum digoxin estimations were done in 98 patients receiving digoxin for heart failure of varied aetiology. Digoxin toxicity or the lack of it was determined on the basis of established electrocardiographic criteria.
Fifty-two patients were classified as 'toxic' and 46 as 'non-toxic'. The difference in the mean digoxin levels between the two groups was highly significant (P< o.OOI). The mean serum digoxin level in 'non-toxic' patients was slightly higher than that found by other investigators. Fairly good correlations have been noted between different dosage schedules and various rhythm disturbances. Death was attributed to digoxin toxicity in only 2 patients who showed electrocardiographic evidence of intoxication at the time of death.
The therapeutic axiom propounded by William Withering (I937) in I785 'let it be continued until it either acts on to the kidneys, the stomach, the pulse or the bowel' remained the major guideline for a long time regarding the use of digitalis glycosides. However, increasing incidence of digitalis toxicity, rising mortality rate attributed to digoxin, and greater appreciation of its hazards made the development of techniques of estimation of serum digoxin level desirable, in order to allow finer control of doses between the therapeutic and toxic levels. Doherty, Perkins, and Flanigan (1967) determined myocardial digoxin in animals as well as in man and established a relatively constant ratio with levels in blood. Smith, Butler, and Haber (I969) suggested a sensitive radioimmunoassay for the estimation of blood digoxin levels in non-toxic and toxic patients.
The (Table i) .
Clinical, electrocardiographic, and biochemical data were obtained in 98 patients of whom 52 were classified as 'toxic' and 46 as 'non-toxic' (Tables 2 and 3 ).
Serum digoxin estimation
This was done by radioimmunoassay (Smith et al., 1969) . The specificity and sensitivity of this method is excellent and it can detect levels of digoxin well below 0.25 nmol/l (Butler, 1972) .
Blood samples
The blood samples in the toxic group were taken at the time of electrocardiographic evidence of toxicity, 6 to 24 hours after administration of the previous dose of digoxin. However, in the non-toxic group the samples were collected 7 hours after the administration of the previous dose of digoxin. Statistical analysis Student's t-test was employed for the analysis of data. (Table 3 ). However, the mean blood urea in the non-toxic group was 5.35 + 3.4 mmol/l and in the toxic group it was 7.57 ± 5.33 mmol/l. The difference was statistically significant (P <o.oi).
Serum digoxin levels
The mean serum digoxin level was higher in the toxic group than in the non-toxic group and the difference was highly significant (P <o.ooi). However, there was no significant difference in the dosage between the two groups (Table 4) . Radioimmunoassay of serum digoxin in relation to digoxin initoxication 62I In 23 out of 52 cases where serum digoxin levels could be estimated before, during, and after therapy with digoxin, the peak rise of serum level was noted during digoxin toxicity as shown in Table 6 . Mortality There were 5 (9.6%) deaths in the toxic group. In 2 (3.8%) cases, the death was attributable to digoxin as they showed electrocardiographic evidence of digoxin toxicity at the time of death in the absence of any other obvious cause.
Dosage forms

Discussion
In recent years the incidence of digitalis intoxication has risen considerably and the report that 3 to 39 per cent of deaths in some series may be attributable to digitalis intoxication (Lely and Van Enter, I972) has brought into question its supremacy in the treatment of congestive heart failure. group may be attributed to impaired renal functions (Table 3) . It is apparent from various studies that serum digoxin concentrations in non-toxic patients usually lie in the o.64-2.56 nmol/l range but that a significant number have serum concentrations in excess of 2.56 nmol/l. However, in a majority of patients with definite digoxin-induced cardiac arrhythmias serum concentrations were noted in the I.79-5.12 nmol/l range (Butler, I972) . In this study, the mean serum digoxin level in non-toxic patients was 2.92 ± i.o6 nmol/l which is slightly higher than the values reported by Smith et al. (I969), Smith and Haber (1970), and Beller et al. (I97i) but closer to the levels reported by Evered, Chapman, and Hayter (I970).
The cause of this difference is not clear as there are no other serum digoxin studies in an Indian population, as far as we know. A possible explanation for this discrepancy, therefore, could be the short stature and lower mean body weight (46 + 10.4 kg in non-toxic group), but similar mean daily dose (0.54 ± 0.I mg/day), of the patients in this series. It is also likely that the biological availability of digoxin in tablets used by us was higher as compared to other workers.
Further factors that may be involved arise from the fact that the rise in serum concentration after administration of digoxin is dependent upon the route of administration, and individual variations in absorption, distribution, and elimination.
There is good correlation between daily maintenance digoxin dosage and serum concentration of the drug as observed in this study (Table 5 ). This relation was fairly good when the patients were given 0.25 mg/day and 0.5 mg/day of digoxin in the non-toxic group of patients. However, when the patients were given 0.75 mg/day of drug daily, the difference between serum digoxin levels of nontoxic and toxic patients was insignificant. This was also observed by other investigators (Smith et al., i969; Smith and Haber, I970; Evered et al., I970).
Smith and Haber (I970) noted fairly good correlation between serum digoxin levels and various categories of arrhythmias, and they found significantly higher levels in patients who had supraventricular tachycardia with block or ventricular arrhythmias, than in patients who had atrial fibrillation with ventricular premature beats or second or third degree AV block. Further they pointed out that in cases with organic disease of the conducting system even low digoxin levels might precipitate significant AV block while in patients with supraventricular tachyarrhythmias higher levels may be required to control the ventricular rate.
Our results conflict with the observations of Smith and Haber (1970) as we found higher levels in patients with second or third degree AV block or ventricular arrhythmias and lower levels in Radioimmunoassay of serum digoxin in relation to digoxin intoxication 623 patients with supraventricular arrhythmias. The production of supraventricular arrhythmias at lower levels of digoxin may be due to pre-existing increased conductivity of cardiac muscle as a result of advanced heart disease, especially when the atria are enlarged because of rheumatic mitral heart disease. In such patients low levels of digoxin may be enough to produce atrial arrhythmias. Thus, it appears that particular serum digoxin levels as such do not determine the type of arrhythmia. It is the pre-existing heart disease either affecting the conduction system or atria, which predisposes the patients and determines the type of arrhythmia at a relatively lower level of digoxin. However, ventricular arrhythmias, especially multifocal ventricular premature beats as observed by us, may require higher levels of digoxin for their manifestation in the absence of significant heart disease. Thus, it should be emphasized that the total clinical picture has to be considered in association with the serum digoxin level to reach a definite conclusion whether a particular cardiac arrhythmia is digoxin induced.
In 23 toxic patients in which serum digoxin levels were estimated before, during, and after toxicity, the highest mean digoxin level was observed during toxicity. This shows that comparatively higher serum drug levels are essential to produce digoxin toxicity, as it disappears with the diminution in the serum digoxin level (Table 6) .
We did not observe a sharp line of demarcation in the serum digoxin levels between the two groups as there was considerable overlap. The range of serum digoxin level in the non-toxic group was 0.77-4.87 nmol/l whereas in the toxic group it ranged from I.I5-I3.06 nmol/l. However, there were i6 cases in the toxic group with serum digoxin levels of more than 5.12 nmol/l. There were only 4 patients in the toxic group who had levels below 2.56 nmol/l but 2I in the non-toxic group. Maximum overlapping therefore was seen in the range of 2.56-5.I2 nmol/l.
In 2 patients (3.8%) of the toxic group death was attributable to digoxin. One had ventricular tachycardia and the other multifocal premature beats. The incidence of death as a direct result of digitalis intoxication in different studies ranges from 3 tO 2I per cent (Rodensky and Wasserman, I96I, Schott, I964; Beller et al., I97I; Agarwal and Agarwal, I972) .
Thus, it appears that there is great variability in serum levels of digoxin and its toxic manifestations. However, if other clinical as well as electrocardiographic manifestations are correlated with the serum digoxin levels, the diagnosis of presence or absence of digitalis intoxication becomes clearer.
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